Classification: Antiasthmatic Action/Kinetics: Inhibits the release of various mediators, such as histamine, leukotriene C4, and prosta-glandin D2, from a variety of cell types associated with asthma. Has no intrinsic bronchodilator, antihis-tamine, or glucocorticoid activity; also, systemic bioavailability is low. tV2: 3.3 hr. About 89% bound to plasma protein; excreted unchanged.
Uses: Maintenance therapy in adults and children (age six and older) with mild to moderate bronchial asthma.
Contraindications: Use for the reversal of acute bronchospasms, especially status asthmaticus. Special Concerns: Use with caution during lactation. Safety and efficacy have not been established in children less than 12 years of age. Nedocromil has not been shown to be able to substitute for the total dose of corticosteroids.
Side Effects: Respiratory: Coughing, pharyngitis, rhinitis, upper respiratory tract infection, increased sputum, bronchitis, dyspnea, bronchospasm. Oral: Dry mouth, unpleasant taste. GI tract: N&V, dyspepsia, abdominal pain, diarrhea. CNS: Dizziness, dys-
phonia. Skin: Rash, sensation of warmth. Body as a whole: Headache, chest pain, fatigue, arthritis. Miscellaneous: Viral infection. How Supplied: Metered dose inhaler: 1.75 mg/inh
Was this article helpful?